White Birch Allergy Shots (SCIT)
White birch (Betula pendula) is the only Fagales species with Phase 3 RCT evidence at both adult and pediatric levels — the Itulazax TT-04 trial in 634 adults and a pediatric Phase 3 in 952 children. Despite this, Itulazax is not FDA-approved in the US, so American patients access equivalent Bet v 1 immunotherapy via non-standardized SCIT injections or off-label sublingual drops.
White Birch Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to white birch — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of white birch allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of white birch immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of white birch extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for white birch allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing white birch extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription white birch immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat white birch allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is White Birch?
The biology, taxonomy, and clinical fingerprint of White Birch — the foundation of how SCIT targets it.
Betula pendula — silver birch — produces pollen in long pendulous catkins from late March through May; aerial concentrations regularly reach several thousand grains per cubic meter at peak season across New England and the Upper Midwest.
- Scientific name
- Betula pendula Roth (synonym B. verrucosa)
- Family
- BetulaceaeBirch family
- Type
- Deciduous tree pollen
- Native to
- Northern and central Europe; widely naturalized across the northern US tier
- Allergen proteins
- Bet v 1 (major) — PR-10, 17.5 kDa, up to 95% IgE reactivity (Moverare 2002); ~30 isoforms; founder of PR-10 superfamilyBet v 2 — Profilin, 14–15 kDa, pan-allergen marker, ~10–20% reactivityBet v 3 — Polcalcin, 24 kDa, 4-EF-handBet v 4 — Polcalcin, 9 kDa, 2-EF-handBet v 6 — Isoflavone reductase, 33 kDaBet v 7 — Cyclophilin, 18 kDa
- Particle size
- 20–24 μm
- Avoidance difficulty
- Nearly impossible
How White Birch Allergy Presents
Symptoms by body system — useful for distinguishing White Birch sensitivity from overlapping allergies and infections.
Respiratory
- Moderate-to-severe sneezing and rhinorrhea during the April–May peak
- Nasal congestion that worsens on high-count days, often exceeding 1,000 grains/m³
- Itchy nasal passages with post-nasal drip and chronic cough
- Allergic asthma exacerbations — wheezing and chest tightness in susceptible patients
- Eustachian tube dysfunction causing ear pressure and hearing changes during peak weeks
Ocular
- Intense bilateral eye itching and watering — a hallmark of birch sensitization
- Conjunctival redness and swelling (allergic conjunctivitis)
- Morning eye crusting from overnight allergen accumulation
- Photophobia and reduced visual comfort on high-pollen days
Dermal
- Oral allergy syndrome (OAS) — lip tingling and throat itch after eating raw apple, hazelnut, peach, cherry, carrot, or celery (Bet v 1 PR-10 cross-reactivity; heat-labile, cooked forms usually tolerated)
- Contact urticaria in highly sensitized patients from direct pollen contact
- Periorbital eczema flares coinciding with peak birch-season pollen counts
Systemic
- Severe fatigue during the 4–6-week birch season — a common complaint in the Upper Midwest and New England
- Sleep disturbance from nighttime nasal obstruction leading to daytime impairment
- Anxiety and dietary restriction from uncertain OAS food triggers
- Quality-of-life impairment comparable to major medical conditions during peak weeks (Anderegg 2021 PNAS — seasons are lengthening)
White birch is the only tree pollen where I can cite a Phase 3 trial in 634 adults and a separate Phase 3 in 952 children — the Itulazax TT-04 program. The catch for US patients is that the SLIT tablet isn't FDA-approved here, so we deliver the same Bet v 1 immunotherapy by injection. Component-resolved testing first — Bet v 1 versus Bet v 2 — tells me whether immunotherapy will work, and for eligible maintenance patients that injection course can now be self-administered at home with Curex, with the first dose and every dose change supervised live over Zoom.
When & Where White Birch Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late April through mid-May across the northern US; February–April in the southeastern range· ~6–8 weeks of clinically significant airborne pollen; climate change has pushed season start ~8 days earlier since 1990 (Anderegg 2021 PNAS)
US Exposure Map
15 high-intensity statesWhat White Birch Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
White birch's Bet v 1 is the founding member of the PR-10 protein superfamily — it cross-reacts with 12+ Fagales tree pollens and more than 20 fresh foods, making oral allergy syndrome virtually universal in birch-sensitized patients. The cross-reactivity follows sequence identity, ranging from 88% with alder to 66% with beech.
Aln g 1 — 88% amino-acid identity with Bet v 1 (Strobl & Lehmann 2024); r=0.994 IgE correlation (Choi 2019)
Que a 1 72–95% identity; 77.4–81.5% Bet v 1 IgE inhibition by white oak extract (Jeong 2016)
Mal d 1 — canonical PR-10 OAS trigger; heat-labile
Cor a 1.04 — heat-labile PR-10 OAS; distinct from anaphylactic Cor a 8/9/14
Jug r 5 — 94% of birch-allergic walnut-allergic patients react (Wangorsch 2017); heat-labile
Birch–Apple–Hazelnut (Bet v 1 PR-10) Oral Allergy Syndrome
Bet v 1 is the structural template for PR-10 proteins expressed in dozens of raw fruits, tree nuts, and vegetables. Birch-sensitized patients with high IgE to Bet v 1 frequently develop tingling, lip swelling, or throat itch when eating raw forms of these foods — symptoms that disappear when the food is cooked or canned because PR-10 proteins denature with heat. This is distinct from anaphylactic food allergy driven by heat-stable storage proteins. A board-certified allergist can separate PR-10 OAS (manageable) from storage-protein anaphylaxis risk (requires strict avoidance + epinephrine carry) via component-resolved testing.
Is SCIT Right for Your White Birch Allergy?
Answer five questions to get a personalized assessment of whether white birch SCIT is likely right for you.
How severe are your spring birch-season symptoms (April–May)?
The White Birch SCIT Protocol
White birch SCIT uses non-standardized B. pendula (or B. verrucosa) extract in a conventional ladder protocol. No US tree pollen extract is FDA-standardized; the Itulazax SLIT-tablet is not FDA-approved in the US as of May 2026, making conventional SCIT injections the primary vehicle for Bet v 1 immunotherapy in American patients.
Injections begin at 1:10,000 w/v and increase incrementally at each visit, guided by local skin reactions. Patients with active PR-10 OAS (especially to raw apple, hazelnut, or peach) may have elevated build-up reactivity and may benefit from a slower up-dosing protocol. Traditionally each injection was followed by a 30-minute observation period in the clinic; with Curex, eligible patients self-administer the same escalation schedule at home, and the first dose plus every dose increase are supervised live over Zoom with a prescribed epinephrine auto-injector confirmed on hand.
Monthly maintenance injections at the target dose sustain long-term Bet v 1 tolerance. Most patients notice clinically meaningful improvement by the second birch season. The Itulazax TT-04 family-level evidence confirms this immunologic target — Bet v 1 at 12 SQ-Bet equivalent dose — produces durable symptom reduction across the entire birch-homologous Fagales group.
Patients who complete the full 3–5 year course may experience lasting benefit for 7–12+ years after stopping. Discontinuation after fewer than 3 years is associated with higher relapse rates. Your allergist will evaluate symptom scores and sensitization levels before recommending whether to stop or extend.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for White Birch SCIT
White birch SCIT has the strongest evidence base of any tree-pollen allergen — anchored by two conventional SCIT RCTs and the landmark Itulazax TT-04 Phase 3 trial. All evidence should be interpreted in the context of non-standardized US extract variability and the fact that the SLIT-tablet trials (Itulazax) were conducted in Europe with a standardized 12 SQ-Bet dose.
- Combined symptom-medication score reduction68%
- Rhinoconjunctivitis symptom score reduction (SCIT RCT)65%Bodtger U et al., Allergy 2002; Arvidsson MB et al., Allergy 2002 (conventional aqueous SCIT)
- Pediatric symptom-medication score improvement60%ALK pediatric Phase 3, N=952 children — EU pediatric extension 2025 (SLIT-tablet)
No conventional SCIT RCT for white birch has been conducted in the US at the scale of Itulazax TT-04; US practice extrapolates from European SCIT RCTs (Bodtger 2002, Arvidsson 2002) and the family-level Itulazax Phase 3 program. The molecular basis for efficacy — Bet v 1 desensitization — is identical whether immunotherapy is delivered by injection or SLIT tablet, providing a strong immunologic rationale for US SCIT practice even in the absence of a US-specific Phase 3 trial.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
White Birch SCIT Side Effects
White birch SCIT side effects follow the standard inhalant SCIT profile with one additional consideration: patients with active PR-10 OAS (raw apple, hazelnut, peach reactions) are more likely to experience build-up reactions, and slower up-dosing should be discussed with your allergist.
Local reactions
4 documentedSystemic reactions
4 documentedA 30-minute post-injection observation accompanies every birch SCIT dose, whether given in a clinic or self-administered at home with Curex — where the first dose and any dose change are supervised live over Zoom. Patients with Bet v 1-driven food OAS should notify their allergist about any recent food reactions or PR-10 food introductions, as these clinical signals can affect up-dosing decisions.
SCIT vs Alternatives for White Birch
White birch-allergic patients have four primary treatment pathways: allergy shots (SCIT) — now available as a weekly at-home injection with Curex — sublingual drops, avoidance measures, and daily medications. The strongest immunotherapy evidence for this allergen, the Itulazax TT-04 program, was a SLIT-tablet trial, but that specific product is not available in the US.
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | High — two conventional SCIT RCTs; family-level Phase 3 (Itulazax TT-04, 634 adults) | High for Bet v 1 SLIT-tablet (Itulazax TT-04, EU only); off-label drops in US are standard extract | Low — birch pollen counts reach thousands of grains/m³; essentially unavoidable at peak | Moderate — antihistamines + intranasal corticosteroids for mild-moderate symptoms |
| 5-yr cost | $3,500–$15,000 over 5 years | Varies by provider; sold as a general sublingual modality, not Curex's product | Low — HEPA, pollen masks, air purifiers | $500–$2,000 over 5 years |
| Duration | 3–5 year course | 3–5 year course | Indefinite — no tolerance change | Indefinite — seasonal use every year |
| Convenience | At-home weekly self-injection with Curex (3–6 months build-up, then monthly); first dose and dose changes supervised live over Zoom | Daily at-home — no clinic required | Moderate inconvenience April–May | High convenience |
| Safety | Excellent — birch serum is USP <797> sterile-compounded, your first dose and dose changes are supervised live over Zoom, a prescribed epinephrine auto-injector is confirmed on hand, and you self-observe 30 minutes | Favorable; no systemic anaphylaxis in Itulazax trials | Safe | Generally safe |
| Lasting effect | 7–12+ years after completion | Emerging — less durability data vs SCIT | None — symptoms return each season | None — must take every season |
SCITBest
SLIT
Avoidance
Medications
SCIT delivers the same Bet v 1 immunotherapy studied in the Itulazax TT-04 Phase 3 program — and with Curex eligible patients self-administer that weekly shot at home for $129/month, with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand. It remains the option with the deepest durability evidence for lasting birch relief.
What White Birch SCIT Actually Costs
Most major US insurers cover birch SCIT under standard allergy immunotherapy benefits when prescribed by a board-certified allergist with supporting skin-prick test or specific IgE (including Bet v 1 component testing). Out-of-pocket cost varies by deductible, co-insurance, and whether extract preparation and injection services are billed separately. Curex at-home IgE testing identifies specific white birch sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your white birch allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
White Birch SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Itulazax (ALK-Abelló) received EMA approval in Europe in 2019 and is approved in 22+ countries plus Canada, but the manufacturer has not sought FDA approval. Per GlobalData analyst commentary reported by BioSpace in February 2020, this is because SLIT tablets have seen 'mediocre uptake' in the US compared with Europe — US patients and insurers have historically preferred SCIT injections, making it commercially unattractive to run a separate US Phase 3 program. As a result, US patients with white birch allergy access Bet v 1 immunotherapy through non-standardized SCIT extracts (the injection route) or off-label sublingual drops, neither of which has the same regulatory approval status as Itulazax in Europe.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.